Last Price$437.20.0%
Market Cap$36.1B
6.5%
Peers median - 0.4%
20.5%
Peers median - 16.4%
6.3%
Peers median - 43.2%
49.4%
Peers median - 8.8%
Competing with IDXX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$36.1B | 7.2 | $219.3 49.8% overvalued | (23.5%) | $3,897.5M | $798.1M | 6.5% | 20.5% | 61.1% | 49.4% | 6.3% | |
$201.0B | 6.5 | $602.4 15.0% undervalued | (9.7%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 8.3% | 63.1% | |
$151.3B | 6.1 | $167.0 18.8% overvalued | (19.4%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$36.5B | 7.4 | $103.7 17.9% overvalued | (11.0%) | $6,533.0M | $1,409.0M | (3.0%) | 21.6% | 65.9% | 14.7% | 55.8% | |
$33.7B | 6.1 | $301.3 63.0% undervalued | (26.5%) | $15.4B | $2,114.0M | 2.5% | 13.7% | 31.4% | 8.8% | 21.7% | |
$27.1B | 7.0 | $869.6 31.5% overvalued | (1.4%) | $3,872.4M | $864.4M | 2.2% | 22.3% | 59.1% | 49.8% | (1,587.1%) | |
$22.2B | 6.5 | $236.1 36.5% overvalued | 7.2% | $2,958.4M | $619.6M | 0.1% | 20.9% | 58.2% | 19.4% | 0.0% | |
$21.2B | 6.1 | $621.0 144.4% undervalued | 17.1% | $13.0B | $1,095.9M | 0.8% | 8.4% | 26.9% | 6.0% | 24.1% | |
$19.6B | 6.0 | $369.8 109.0% undervalued | 44.2% | $9,872.0M | $909.0M | 6.7% | 9.2% | 32.4% | 8.8% | 102.2% | |
$18.5B | 6.0 | $70.9 50.4% overvalued | 58.6% | $1,532.0M | ($33.2M) | 54.9% | (2.2%) | 57.7% | (44.9%) | 54.2% | |
$13.9B | 6.2 | $147.2 74.8% undervalued | (37.1%) | $4,372.0M | $696.0M | (2.9%) | 15.9% | 65.4% | 34.6% | 93.8% |
Compare IDXX Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
IDEXX Laboratories, Inc.IDXX
9.2x
8.7%
25.2%
23.1%
Median Peer Set
5.6x
(1.7%)
(7.2%)
11.6%
Agilent Technologies, Inc.A
5.9x
(4.7%)
5.0%
19.8%
Quest Diagnostics IncorporatedDGX
2.6x
(6.4%)
(6.5%)
9.2%
Danaher CorporationDHR
6.9x
(0.1%)
(17.9%)
16.3%
Illumina, Inc.ILMN
3.5x
(2.9%)
4.6%
(28.0%)
IQVIA Holdings Inc.IQV
2.2x
2.8%
2.4%
8.9%
Laboratory Corporation of America HoldingsLH
N/A
(18.3%)
(65.8%)
3.4%
Mettler-Toledo International Inc.MTD
7.5x
2.2%
12.7%
22.3%
Natera, Inc.NTRA
11.8x
32.0%
(32.1%)
(40.2%)
Thermo Fisher Scientific Inc.TMO
5.3x
(4.6%)
(12.4%)
14.0%
Waters CorporationWAT
7.4x
(0.5%)
(7.9%)
21.7%
Compare IDXX Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does IDEXX Laboratories, Inc. (IDXX) revenue growth compare to peers and the industry?
IDEXX Laboratories, Inc. (IDXX) revenue growth is 6.5%, compared to the peers' median of 0.4%.
2. How does IDEXX Laboratories, Inc. (IDXX) Free Cash Flow (FCF) margin compare to peers and the industry?
IDEXX Laboratories, Inc. (IDXX) FCF margin is 20.5%, compared to the peers' median of 16.4%.
3. How does IDEXX Laboratories, Inc. (IDXX) Total Debt to Equity ratio compare to peers and the industry?
IDEXX Laboratories, Inc. (IDXX) Total Debt to Equity ratio is 6.3%, compared to the peers' median of 43.2%.
4. How does IDEXX Laboratories, Inc. (IDXX) ROIC (Return on Invested Capital) compare to peers and the industry?
IDEXX Laboratories, Inc. (IDXX) ROIC is 49.4%, compared to the peers' median of 8.8%.